Updates are available Correction dated 2023-11-23
Click to view Correction: https://doi.org/10.1007/s00259-023-06538-0
-
Authors
Schoenmakers, Jorrit W.A.
López‑Álvarez, Marina
IJpma, Frank F.A.
Wouthuyzen-Bakker, Marjan
McNamara, James O. 2nd
van Oosten, Marleen
Jutte, Paul C.
van Dijl, Jan Maarten http://orcid.org/0000-0002-5688-8438
-
Funding
Funding for this research was provided by:
Graduate School of Medical Sciences of the University of Groningen
H2020 Marie Skłodowska-Curie Actions (713660)
- License Information
-
More Information
Article History
Received: 17 April 2023
Accepted: 30 October 2023
First Online: 14 November 2023
Change Date: 23 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00259-023-06538-0
Declarations
:
: The Medical Ethical Review Board (Medisch Ethische Toetsingscommissie; METc) provided permission for collection and analysis of surplus patient-derived synovial fluid samples (METc 2021/ 407) and osteosynthesis materials (METc 2016/ 481). The samples were treated pseudo-anonymously. No clinical decisions were made based on the results of this study.
: Patients involved in donating osteosynthesis materials gave written informed consent to participate in this study, which included the use of pseudo-anonymized data and samples for the purpose of research and publication. Due to the UMCG’s opt-out research consent policy, informed written consent for the use of patient diagnostic surplus materials (i.e., synovial fluid samples) was not necessary as, unless stated otherwise in the individual patient’s medical files, consent is given trough this policy.
: James O. McNamara is the founder and CEO of Nuclease Probe Technologies. The other authors have no conflicts of interest to disclose.
